abc008
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
2
Phase 4
0
Earliest trial started May 25, 2021 (NCT04659031)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06450886 | Phase 2/Phase 3 (Phase 3) | Oct 21, 2024 | Abcuro, Inc. |
| NCT05721573 | Phase 2/Phase 3 (Phase 3) | Feb 28, 2023 | Abcuro, Inc., Syneos Health |
| NCT05532722 | Phase 1/Phase 2 (Phase 2) | Sep 28, 2022 | Abcuro, Inc. |
| NCT04659031 | Phase 1 | May 25, 2021 | Abcuro, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abcuro, Inc. | For profit | 4 | 4 | 3 | 2021 |
| Syneos Health | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1